Authors : Renuka Gudepu

Volume/Issue : Volume 11 - 2026, Issue 8 - August

Google Scholar : https://tinyurl.com/4stbmyba

DOI : https://doi.org/10.38124/ijisrt/26aug1528

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : The human gut harbours a complex and diverse community of microorganisms that plays an important role in digestion, immune regulation, metabolism, and maintenance of intestinal health. A healthy gut microbiota is dominated by beneficial microorganisms, particularly anaerobic bacteria such as Faecalibacterium prausnitzii, Bacteroides, Lactobacillus, and Bifidobacterium, which contribute to the production of short-chain fatty acids and maintenance of the intestinal barrier. In inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, this microbial balance is disturbed, resulting in a condition known as gut microbiota dysbiosis. Dysbiosis is commonly associated with a reduction in beneficial anaerobic bacteria and an increase in potentially harmful or oxygen-tolerant microorganisms, including certain strains of Escherichia coli and Enterococcus. These changes may alter intestinal oxygen availability, microbial diversity, metabolite production, epithelial barrier function, and immune responses, thereby contributing to intestinal inflammation and disease progression. Increasing evidence suggests that microbial alterations may occur early in IBD and may contribute to both disease initiation and progression. This review summarizes the major changes in gut microbiota associated with IBD, discusses the mechanisms through which dysbiosis may promote intestinal inflammation, and highlights its role in disease pathogenesis. The review also discusses emerging therapeutic approaches aimed at restoring microbial balance, including probiotics, prebiotics, dietary interventions, faecal microbiota transplantation, and other microbiota-targeted strategies. Understanding the relationship between gut microbiota and IBD may provide opportunities for improved diagnosis, prevention, and development of personalised therapeutic approaches.

Keywords : Gut Microbiota; Dysbiosis; Inflammatory Bowel Disease; Crohn’s Disease; Ulcerative Colitis; Anaerobic Bacteria; Intestinal Inflammation; Gut Barrier; Short-Chain Fatty Acids; Probiotics; Fecal Microbiota Transplantation.

References :

1. Ananthakrishnan, A. N., Bernstein, C. N., Iliopoulos, D., Macpherson, A., Neurath, M. F., Pai, R. K., & Rehm, H. L. (2018). Environmental triggers in IBD: A review of progress and evidence. Nature Reviews Gastroenterology & Hepatology, 15, 39–49.
2. Dalal, S. R., & Chang, E. B. (2014). The microbial basis of inflammatory bowel diseases. Journal of Clinical Investigation, 124, 4190–4196.
3. Dalal, S. R., & Chang, E. B. (2014). The microbial basis of inflammatory bowel diseases. Journal of Clinical Investigation, 124, 4190–4196.
4. Halfvarson, J., Brislawn, C. J., Lamendella, R., Vázquez-Baeza, Y., Walters, W. A., Bramer, L. M., D’Amato, M., et al. (2017). Dynamics of the human gut microbiome in inflammatory bowel disease. Nature Microbiology, 2, 17004.
5. Halfvarson, J., Brislawn, C. J., Lamendella, R., Vázquez-Baeza, Y., Walters, W. A., Bramer, L. M., D’Amato, M., et al. (2017). Dynamics of the human gut microbiome in inflammatory bowel disease. Nature Microbiology, 2, 17004.
6. Halfvarson, J., Brislawn, C. J., Lamendella, R., Vázquez-Baeza, Y., Walters, W. A., Bramer, L. M., D’Amato, M., et al. (2017). Dynamics of the human gut microbiome in inflammatory bowel disease. Nature Microbiology, 2, 17004.
7. He, X., Zhao, S., & Li, Y. (2021). Faecalibacterium prausnitzii: A next-generation probiotic in gut disease improvement. Canadian Journal of Infectious Diseases and Medical Microbiology, 2021, 6666114.
8. Iliev, I. D., & Cadwell, K. (2021). Effects of intestinal fungi and the microbiota on mucosal immunity and gastrointestinal inflammation. Nature Reviews Immunology, 21, 409–420.
9. Koh, A., De Vadder, F., Kovatcheva-Datchary, P., & Bäckhed, F. (2016). From dietary fiber to host physiology: Short-chain fatty acids as key bacterial metabolites. Cell, 165, 1332–1345.
10. Kostic, A. D., Xavier, R. J., & Gevers, D. (2014). The microbiome in inflammatory bowel disease: Current status and the future ahead. Gastroenterology, 146, 1489–1499.
11. Lavelle, A., & Sokol, H. (2020). Gut microbiota-derived metabolites as key actors in inflammatory bowel disease. Nature Reviews Gastroenterology & Hepatology, 17, 223–237.
12. Lebeer, S., Vanderleyden, J., & De Keersmaecker, S. C. J. (2008). Genes and molecules of lactobacilli supporting probiotic action. Microbiology and Molecular Biology Reviews, 72, 728–764.
13. Lloyd-Price, J., Arze, C., Ananthakrishnan, A. N., Schirmer, M., Avila-Pacheco, J., Poon, T. W., Andrews, E., et al. (2019). Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature, 569, 655–662.
14. Ma, J., Piao, X., Mahfuz, S., Long, S., & Wang, J. (2022). The interaction among gut microbes, the intestinal barrier and short chain fatty acids. Animal Nutrition, 9, 159–174.
15. Manichanh, C., Borruel, N., Casellas, F., & Guarner, F. (2012). The gut microbiota in IBD. Nature Reviews Gastroenterology & Hepatology, 9, 599–608.
16. Mann, E. R., et al. (2024). Short-chain fatty acids: Linking diet, the microbiome and immunity. Nature Reviews Immunology, 24.
17. Matsuoka, K., & Kanai, T. (2015). The gut microbiota and inflammatory bowel disease. Seminars in Immunopathology, 37, 47–55.
18. Miquel, S., Lagrafeuille, R., Soulet, C., Dore, J., & Blottière, H. M. (2013). Anti-inflammatory effects of Faecalibacterium prausnitzii and its potential use as a therapeutic agent in inflammatory bowel disease. Microbial Cell Factories, 12, 1–11.
19. Mukhopadhya, I., & Louis, P. (2025). Gut microbiota-derived short-chain fatty acids and their role in human health and disease. Nature Reviews Microbiology, 23, 635–651.
20. Ni, J., Wu, G. D., Albenberg, L., & Tomov, V. T. (2017). Gut microbiota and IBD: Causation or correlation? Nature Reviews Gastroenterology & Hepatology, 14, 573–584.
21. O’Callaghan, A., & van Sinderen, D. (2016). Bifidobacteria and their role as members of the human gut microbiota. Frontiers in Microbiology, 7, 925.
22. Parada Venegas, D., de la Fuente, M. K., Landskron, G., González, M. J., Quera, R., Dijkstra, G., Harmsen, H. J. M., Faber, K. N., & Hermoso, M. A. (2019). Short chain fatty acids and the microbiota: New metabolic and immune functions in intestinal inflammation and nutrition. Frontiers in Immunology, 10, 277.
23. Rigottier-Gois, L. (2013). Dysbiosis in inflammatory bowel diseases: The oxygen hypothesis. ISME Journal, 7, 1256–1261.
24. Round, J. L., & Mazmanian, S. K. (2009). The gut microbiota shapes intestinal immune responses during health and disease. Nature Reviews Immunology, 9, 313–323.
25. Sartor, R. B., & Wu, G. D. (2017). Roles for intestinal bacteria, viruses, and fungi in pathogenesis of inflammatory bowel diseases and therapeutic approaches. Gastroenterology, 152, 327–339.
26. Schirmer, M., Garner, A., Vlamakis, H., & Xavier, R. J. (2019). Microbial genes and pathways in inflammatory bowel disease. Nature Reviews Microbiology, 17, 497–511.
27. Sokol, H., et al. (2017). The microbiota in inflammatory bowel disease. Nature Reviews Gastroenterology & Hepatology, 14, 205–217.
28. Sokol, H., Pigneur, B., Watte­rlot, L., Lakhdari, O., Bermúdez-Humarán, L. G., Gratadoux, J. J., Blugeon, S., et al. (2008). Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proceedings of the National Academy of Sciences of the United States of America, 105, 16731–1673
29. Wexler, H. M. (2007). Bacteroides: The good, the bad, and the nitty-gritty. Clinical Microbiology Reviews, 20, 593–621.